Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5333938 | 0.81 | KDR (0.54) | KDRAURKBAURKANTRK1CDK1 | |
| SCHEMBL5339174 | 0.80 | SMN1; SMN2 (0.51) | KDRAURKBAURKACSF1RNTRK1 | |
| SCHEMBL5345816 | 0.77 | KDR (0.65) | KDRAURKBAURKACSF1RNTRK1 | |
| SCHEMBL5429189 | 0.76 | KDR (0.73) | KDRAURKBAURKACSF1RNTRK1 | |
| SCHEMBL5454230 | 0.75 | NTRK1 (0.56) | KDRAURKBCSF1RNTRK1 | |
| SCHEMBL5457893 | 0.73 | NTRK1 (0.63) | KDRAURKBAURKACSF1RNTRK1 | |
| SCHEMBL5338760 | 0.72 | NTRK1 (0.66) | KDRAURKBAURKACSF1RNTRK1 | |
| SCHEMBL23900656 | 0.72 | MTOR (0.42) | KDRCLK2LRRK2AURKBAURKA | |
| SCHEMBL5425879 | 0.71 | CCNC (0.43) | KDRCLK2LRRK2AURKBAURKA | |
| SCHEMBL5442522 | 0.71 | NTRK1 (0.58) | KDRCSF1RNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | KDR 555/4885CLK2 989/4885LRRK2 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.